In vitro activities of a new fluoroquinolone derivative highly active against Chlamydia trachomatis

Area of Science:

• Microbiology
• Medicinal Chemistry
• Infectious Diseases

Background:

• Chlamydia trachomatis is a significant human pathogen causing trachoma, a leading cause of preventable blindness, and the most common bacterial sexually transmitted infection globally.
• Current treatments face challenges, necessitating the development of novel therapeutic strategies against this bacterium.

Purpose of the Study:

• To design and synthesize a novel inhibitor targeting Chlamydia trachomatis.
• To leverage the bacterium's iron dependency and a known antibiotic in the inhibitor's design.
• To evaluate the efficacy of the new compound against Chlamydia trachomatis and other pathogenic bacteria.

Main Methods:

• A conjugate of 8-hydroxyquinoline and ciprofloxacin was synthesized via a short synthetic pathway.
• The synthesized compound was tested against a panel of bacteria, including Chlamydia trachomatis and the ESKAPE pathogens.
• Spectrophotometric titration was used to demonstrate the compound's ability to complex iron(III).

Main Results:

• The 8-hydroxyquinoline-ciprofloxacin conjugate exhibited higher anti-Chlamydia activity compared to ciprofloxacin alone.
• The enhanced activity appears linked to the fluoroquinolone component, which also facilitates iron(III) complexation.
• The compound showed activity against other pathogenic bacteria, including members of the ESKAPE group.

Conclusions:

• The novel 8-hydroxyquinoline-ciprofloxacin conjugate represents a promising new therapeutic agent against Chlamydia trachomatis infections.
• The drug's efficacy is potentially enhanced by its iron-chelating properties and the fluoroquinolone moiety.
• This approach offers a potential strategy for developing new antimicrobials targeting iron-dependent bacteria.